Advertisement

Topics

Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to Co-Develop Multiple Novel Biologic Therapies

19:30 EDT 20 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Agreement encompasses joint funding and co-development Immediate program focus on TAK-671, a therapeutic candidate intended to address unmet need in severe acute pancreatitis. Samsung Bioepis...

Other Sources for this Article

Media Contacts:
Samsung Bioepis
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com
-
Takeda
Kelly Schlemm – USA
+1-617-551-8865
kelly.schlemm@takeda.com

NEXT ARTICLE

More From BioPortfolio on "Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to Co-Develop Multiple Novel Biologic Therapies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...